Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of artemisinin compound in preparation of drugs for treating ITP

An artemisinin and compound technology, which is applied to the application field of artemisinin compounds in the preparation of medicines for the treatment of immune thrombocytopenia, and achieves the effects of high cost-effectiveness, reduced probability of serious complications, and good effects.

Inactive Publication Date: 2019-06-28
广州博奥技术有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In fact, there are currently no effective drugs for the treatment of immune thrombocytopenia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0010] Below in conjunction with clinical examples, further illustrate the technical solution of the present invention.

[0011] Treat 30 patients with immune thrombocytopenia with artemisinin drugs (preferably artemisinin or dihydroartemisinin), and take 10 mg to 2000 mg of artemisinin drugs orally or by injection per day according to the condition, preferably 50 to 500 mg / day , have achieved good clinical efficacy, and no adverse events occurred. It shows that oral administration or injection of artemisinin drugs can effectively treat immune thrombocytopenia.

[0012] Specific cases:

[0013] Case 1: The patient was an elderly woman who was diagnosed with ITP in May 2013. He was given glucocorticoid, gamma globulin and drug immunosuppressive therapy for many times successively, and his condition relapsed many times when the hormone was withdrawn in outpatient follow-up. From January 2015, artesunate 100 mg was administered orally once a day, and blood routine, electrocard...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an artemisinin compound in preparation of drugs for treating ITP. It is unexpectedly discovered in clinical trials that blood platelet count holding time can beprolonged when drugs of artemisinin, especially artesunate or dihydroartemisinin treat patients with immune thrombocytopenia and patients with relapse of the immune thrombocytopenia, and it is indicated that the artemisinin drugs have a good therapeutic effect on the immune thrombocytopenia. Further studies show that the combination of the artemisinin drugs and other drugs, such as the combinationof the artemisinin drugs and glucocorticoids, can further reduce the dosage of glucocorticoid, gamma globulin and the like for treatment, thereby reducing the treatment cost of the patients and reducing the probability of significant complications. Reticulocytes as a toxicity sensitive index of the artemisinin drugs are strictly observed by the inventor, it is found that no significant differenceexists before and after the treatment, and it is further showed that the artemisinin drugs have good safety.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the new application of compounds, in particular to the application of artemisinin compounds in the preparation of drugs for treating immune thrombocytopenia (ITP). Background technique [0002] Immune thrombocytopenia (ITP), formerly known as idiopathic thrombocytopenic purpura, is an acquired autoimmune disease. It is the most common bleeding disorder caused by decreased platelet count seen clinically. The main pathogenesis of ITP is excessive destruction of platelets mediated by humoral and cellular immunity, abnormal quantity and quality of megakaryocytes mediated by humoral and cellular immunity, and insufficient platelet production. The current first-line treatment of ITP includes: 1. Adrenal glucocorticoid 2. Gamma globulin. Second-line treatment for ITP includes: 1. Splenectomy 2. Drug therapy: azathioprine, cyclosporine A, danazol, anti-CD-20 monoclonal antibody (rituximab), ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/366A61K31/357A61P7/04A61P37/02
Inventor 符卓韬孟聪符林春许铮弟
Owner 广州博奥技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com